医学
肝细胞癌
肝移植
内科学
肝病
入射(几何)
肿瘤科
胃肠病学
移植
物理
光学
作者
Leva Gorji,Zachary J. Brown,Ashley Limkemann,Austin Schenk,Timothy M. Pawlik
出处
期刊:JAMA Surgery
[American Medical Association]
日期:2023-12-06
卷期号:159 (2): 211-211
被引量:17
标识
DOI:10.1001/jamasurg.2023.6083
摘要
Importance Liver malignancies are an increasing global health concern with a high mortality. We review outcomes following liver transplant for primary and secondary hepatic malignancies. Observations Transplant may be a suitable treatment option for primary and secondary hepatic malignancies in well-selected patient populations. Conclusions and Relevance Many patients with primary or secondary liver tumors are not eligible for liver resection because of advanced underlying liver disease or high tumor burden, precluding complete tumor clearance. Although liver transplant has been a long-standing treatment modality for patients with hepatocellular carcinoma, recently transplant has been considered for patients with other malignant diagnoses. In particular, while well-established for hepatocellular carcinoma and select patients with perihilar cholangiocarcinoma, transplant has been increasingly used to treat patients with intrahepatic cholangiocarcinoma, as well as metastatic disease from colorectal liver and neuroendocrine primary tumors. Because of the limited availability of grafts and the number of patients on the waiting list, optimal selection criteria must be further defined. The ethics of organ allocation to individuals who may benefit from prolonged survival after transplant yet have a high incidence of recurrence, as well as the role of living donation, need to be further discerned in the setting of transplant oncology.
科研通智能强力驱动
Strongly Powered by AbleSci AI